全文获取类型
收费全文 | 65篇 |
免费 | 0篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 3篇 |
临床医学 | 1篇 |
内科学 | 8篇 |
特种医学 | 46篇 |
外科学 | 1篇 |
综合类 | 4篇 |
预防医学 | 1篇 |
出版年
2013年 | 3篇 |
2012年 | 1篇 |
2008年 | 2篇 |
2007年 | 2篇 |
2006年 | 2篇 |
2005年 | 7篇 |
2004年 | 3篇 |
2000年 | 2篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1989年 | 1篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1972年 | 3篇 |
1971年 | 4篇 |
1970年 | 3篇 |
1969年 | 5篇 |
1968年 | 3篇 |
1967年 | 3篇 |
1966年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有65条查询结果,搜索用时 156 毫秒
41.
42.
Trisomy 13-15 总被引:1,自引:0,他引:1
43.
44.
45.
46.
Ederhy S Di Angelantonio E Mallat Z Hugel B Janower S Meuleman C Boccara F Freyssinet JM Tedgui A Cohen A 《The American journal of cardiology》2007,100(6):989-994
Circulating procoagulant microparticles (MPs) arising from cell activation or fragmentation during apoptosis retain procoagulant properties and are increased in severe thrombotic states. We investigated whether circulating procoagulant MP levels would be increased in nonvalvular atrial fibrillation (AF). Using a hospital case-control study design, circulating procoagulant MP levels were measured in 45 patients with permanent and/or persistent AF who were not receiving anticoagulant therapy and 90 age-matched control subjects (45 with cardiovascular risk factors and 45 without). Annexin V-positive MP levels (expressed as nanomoles per liter of phosphatidylserine equivalent) were higher in patients with AF (median 9.3, interquartile range 6.8 to 17.3 nmol/L) than in control subjects with cardiovascular risk factors (median 4.9, interquartile range 3.7 to 8.4 nmol/L) and control subjects without cardiovascular risk factors (median 3.2, interquantile range 2.3 to 4.6 nmol/L; p<0.001). Platelet-derived MPs (captured with antiglycoprotein Ib) and endothelial-derived MPs (captured with anti-CD31) were similar in patients with AF and control subjects with cardiovascular risk factors but were significantly higher than in control subjects without cardiovascular risk factors. On multiple regression analysis, the presence of AF was a strong predictor of annexin V-positive MP level (p<.001). In conclusion, circulating procoagulant MPs are increased in persistent and/or permanent AF and might reflect a hypercoagulable state that could contribute to atrial thrombosis and thromboembolism. 相似文献
47.
Ederhy S Meuleman C Hammoudi N Janower S Boccara F Cohen A 《Presse medicale (Paris, France : 1983)》2005,34(18):1315-1324
Atrial fibrillation, the most commonly encountered arrhythmia in clinical practice, is associated with substantial morbidity and mortality. Its incidence and prevalence are increasing, and it represents a growing clinical and economic burden. Recent research has highlighted new approaches to both pharmacological and non-pharmacological management. Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%. Overall, in high-risk patients, warfarin was better than aspirin in preventing strokes, with a relative risk reduction of 36%, but the risk of major hemorrhage with warfarin was twice that with aspirin. Anticoagulation treatment needs to be tailored individually for patients on the basis of age, comorbidities, and contraindications. However, warfarin remains under-prescribed in clinical practice, for reasons related to patients (comorbidities) and physicians. The limitations of warfarin treatment have prompted the development of new anticoagulants with predictable pharmacokinetics that do not require as frequent monitoring. Ximelagatran, an oral direct thrombin inhibitor, was compared with warfarin in the SPORTIF program, which found both agents to be broadly effective in the prevention of embolic events, but observed abnormal liver function tests in 6% of patients on ximelagatran. Liver function monitoring during treatment is thus needed. Idraparinux, a factor Xa inhibitor administered by once weekly subcutaneous injections, is being evaluated in patients with atrial fibrillation. The ACTIVE trial is currently assessing the role of aspirin plus clopidogrel, compared with adjusted dose warfarin, in the prevention of vascular events in high-risk patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs interfere with atrial remodeling and show promise in atrial fibrillation, as suggested in the LIFE trial. Preliminary studies suggest that statins may reduce the risk of recurrence after electrical cardioversion. Finally, percutaneous methods for occlusion of the left atrial appendage are currently under investigation in patients at high risk of thromboembolism but with contraindications for chronic warfarin. 相似文献
48.
Janower ML 《Academic radiology》2004,11(6):714; author reply 714
49.
50.
A Guay M L Janower R W Bain F J McCready 《The American journal of the medical sciences》1976,271(2):239-234
A case of Bueger's disease causing ischemic colitis with perforation in a 32-year-old male is presented. Abdominal angiography demonstrated occlusion of the vasculature supplying the involved transverse colon. The association of Buerger's disease with ischemic colitis is emphasized. 相似文献